RAPID:Antibody-Based Nanoplasmonic Barcode Biosensors for COVID-19 Detection

RAPID：用于检测 COVID-19 的基于抗体的纳米等离子体条形码生物传感器

• 批准号: 2027066
• 负责人: Robert Pantazes
• 金额: $ 19.97万
• 依托单位: Auburn University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2021-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2027066&HistoricalAwards=false
• 关键词: RAPID; Antibody; Based; Nanoplasmonic; Barcode

Recent weeks and months have seen the emergence of COVID-19 as a major threat to health on a global scale. One major challenge associated with combating this disease is the lack of a rapid diagnostic device. Although current tests are sensitive, they require specially equipped laboratories and can take several days to provide results. This project aims to identify and validate antibodies for use in real-time, point-of-care, COVID-19 biosensor devices. Such devices could allow doctors and other healthcare professionals to immediately diagnose infected individuals and get them the treatment they need while more effectively containing the spread of this pandemic.SARS-CoV-2 is the viral cause of the COVID-19 illness. An antibody-based nanoplasmonic barcode biosensor could a provide real-time, point-of-care diagnostic device. This project will develop such a sensor. The first objective is the discovery of SARS-CoV-2 binding antibodies. To ensure a sufficient diversity of antibodies are identified, three parallel discovery pathways will be pursued: 1) the identification of antibodies that cross-react with SARS-CoV-2 and MERS-CoV spike proteins, 2) the rational engineering of anti- SARS-CoV-1 antibodies to bind SARS-CoV-2, and 3) the in silico, de novo design of novel SARS-CoV-2 antibodies. About four antibody pairs will be selected from the antibodies discovered through the three complementary approaches. The pairs will be used for SARS-CoV-2 detection on the basis of their affinity measured by ELISA and surface plasmon resonance and of the selectivity of their binding to unique epitopes, as monitored by competition ELISA. Finally, the antibody pairs will be used in the design and evaluation of SARS-CoV-2 nanoplasmonic biosensors. Nanoparticle signals will only be detected by the biosensors in the presence of virus. The proposed research will enable the more rapid detection of SARS-CoV-2 compared to current diagnostic tests, resulting in a better understanding of its spread and more effective containment.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

最近几周和几个月，新冠肺炎 (COVID-19) 的出现已成为全球范围内对健康的重大威胁。对抗这种疾病的一个主要挑战是缺乏快速诊断设备。尽管当前的测试很敏感，但它们需要专门配备的实验室，并且可能需要几天的时间才能提供结果。该项目旨在识别和验证用于实时护理点 COVID-19 生物传感器设备的抗体。此类设备可以让医生和其他医疗保健专业人员立即诊断感染者并为他们提供所需的治疗，同时更有效地遏制这一流行病的传播。SARS-CoV-2 是导致 COVID-19 疾病的病毒原因。基于抗体的纳米等离子体条形码生物传感器可以提供实时的护理点诊断设备。该项目将开发这样一种传感器。第一个目标是发现 SARS-CoV-2 结合抗体。为了确保鉴定出足够多样性的抗体，将寻求三个平行的发现途径：1）鉴定与 SARS-CoV-2 和 MERS-CoV 刺突蛋白交叉反应的抗体，2）合理设计抗 SARS-CoV-1 抗体以结合 SARS-CoV-2，以及 3）新型 SARS-CoV-2 抗体的计算机从头设计。将从通过三种互补方法发现的抗体中选择大约四个抗体对。这些对将用于 SARS-CoV-2 检测，其依据是通过 ELISA 和表面等离振子共振测量的亲和力，以及通过竞争 ELISA 监测的它们与独特表位结合的选择性。最后，抗体对将用于 SARS-CoV-2 纳米等离子体生物传感器的设计和评估。只有在病毒存在的情况下，生物传感器才会检测到纳米颗粒信号。与当前的诊断测试相比，拟议的研究将能够更快速地检测 SARS-CoV-2，从而更好地了解其传播和更有效的遏制。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。